<DOC>
	<DOC>NCT02657915</DOC>
	<brief_summary>The primary objective of the study is to assess full-field visual evoked potential (FF-VEP) latency in subjects who were enrolled in Study 215ON201 (NCT01721161) 2 years (+ 4 months) after the last study visit. The secondary objective is to assess clinical progression and severity of central nervous system (CNS) demyelinating disease in subjects who were enrolled in Study 215ON201 2 years (+ 4 months) after the last study visit. No study drug dosing is planned for this study.</brief_summary>
	<brief_title>Long-Term Assessment of Remyelinating Therapy</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Key Must have participated in Study 215ON201 and received at least 1 dose of BIIB033 or placebo, as per protocol, within 2 years (+ 4 months) from Day 1 of this study (2 years from Week 32 or projected Week 32 visit, if the subject did not complete all visits in Study 215ON201). Key Not previously enrolled in Study 215ON201 Subjects with recent kidney function, such as serum creatinine above upper limit of normal range, will not be allowed to receive administration of Gd but will otherwise be allowed to participate in the study, including magnetic resonance imaging (MRI) assessments not requiring the use of Gd. Female subjects must have had a recent pregnancy test and must not be breastfeeding prior to MRI assessments with Gd. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FF-VEP</keyword>
	<keyword>mfVEP</keyword>
	<keyword>Human anti-LINGO-1</keyword>
	<keyword>BIIB033</keyword>
	<keyword>AON</keyword>
</DOC>